•
Sep 24, 2022

Hologic Q4 2022 Earnings Report

Hologic delivered excellent results, significantly exceeding expectations, and topping off another tremendous year.

Key Takeaways

Hologic's Q4 2022 revenue reached $953.3 million, a decrease of 27.6% compared to the previous year, driven by lower COVID-19 assay sales and supply chain challenges. GAAP diluted EPS was $0.47, while Non-GAAP diluted EPS was $0.82, both exceeding expectations. The company anticipates strong growth in core businesses for fiscal year 2023.

Revenue of $953.3 million decreased (27.6%) for the quarter, or (25.6%) in constant currency, primarily driven by lower sales of COVID-19 assays and supply chain challenges related to semiconductor chips in our Breast Health business compared to the prior year period.

Diagnostics revenue decreased (37.8%), or (35.6%) in constant currency, primarily driven by lower sales of COVID-19 assays compared to the prior year period. Excluding COVID-19 revenues, Diagnostics revenue grew 11.1% on an organic, constant currency basis.

Molecular Diagnostics revenue declined (43.2%), or (41.3%) in constant currency, primarily driven by lower sales of COVID-19 assays compared to the prior year period. Excluding COVID-19 revenues, Molecular Diagnostics revenue grew 17.2% on an organic, constant currency basis.

Breast Health revenue, as expected, declined (17.7%), or (16.0%) in constant currency, primarily due to lower gantry revenue resulting from semiconductor chip shortages.

Total Revenue
$953M
Previous year: $1.32B
-27.6%
EPS
$0.82
Previous year: $1.61
-49.1%
GAAP Gross Margin
54%
Non-GAAP Gross Margin
62.5%
Operating Margin
14.8%
Gross Profit
$515M
Previous year: $828M
-37.8%
Cash and Equivalents
$2.34B
Previous year: $1.17B
+99.9%
Free Cash Flow
$98M
Previous year: $440M
-77.7%
Total Assets
$9.07B
Previous year: $8.92B
+1.7%

Hologic

Hologic

Hologic Revenue by Segment

Hologic Revenue by Geographic Location

Forward Guidance

Hologic provided financial guidance for Q1 and full year 2023, anticipating continued strength in base diagnostics and surgical businesses, along with a strong rebound in the breast health business. The guidance assumes low double-digit constant currency organic revenue growth ex. COVID-19 in each division for full-year fiscal 2023.

Positive Outlook

  • Continued strength in base Diagnostics business
  • Continued strength in Surgical businesses
  • Strong rebound in Breast Health business over the course of the year
  • Low double-digit constant currency organic revenue growth ex. COVID-19 in each division for full-year fiscal 2023.
  • Full year non-GAAP tax rate of approximately 19.0%

Challenges Ahead

  • Q1 2023 Revenue $940 - $990 (36.1%) to (32.7%)
  • Q1 2023 GAAP EPS $0.60 - $0.70 (69.2%) to (64.1%)
  • Q1 2023 Non-GAAP EPS $0.80 - $0.90 (63.1%) to (58.5%)
  • Fiscal 2023 Revenue $3,700 - $3,900 (23.9%) to (19.8%)
  • Fiscal 2023 GAAP EPS $2.51 - $2.81 (51.1%) to (45.2%)

Revenue & Expenses

Visualization of income flow from segment revenue to net income